Program
aglatimagene besadenovec
Also written as “AdV-tk”, “Aglatimagene besadenovec” and “Aglatimagene besadenovec + valacyclovir”.
Its studies are mostly in Prostatic Neoplasms · Carcinoma, Non-Small-Cell Lung · Glioblastoma · Lung Neoplasms · Ependymoma, led by Candel Therapeutics.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Candel Therapeutics | 126 open or running | phase 3since Sep 19, 2011 | Dec 27, 2007 | Feb 2027phase 2 · NCT07332000 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 27, 2007First study: phase 2 study in GliomaFirst studyNCT00589875 · 52 enrolled · United States
- Mar 5, 20082 phase 1 studiesNCT00634231, NCT00638612
- Sep 9, 2008Phase 1 study in GliomaNCT00751270 · 15 enrolled · United States
- Sep 19, 2011Phase 3 study in Prostatic NeoplasmsNCT01436968 · 711 enrolled · United States, Puerto Rico
- Nov 19, 2013Phase 1 study in Pleural Effusion, MalignantNCT01997190 · 19 enrolled · United States
- Apr 14, 2015Phase 2 study in Borderline Resectable Pancreatic AdenocarcinomaNCT02446093 · 54 enrolled · United States, Mexico
- May 6, 2016Phase 2 study in Prostatic NeoplasmsNCT02768363 · 187 enrolled · United States, Mexico
- Apr 24, 2017Phase 1 study in Lung NeoplasmsNCT03131037 · 12 enrolled · United States
- Jul 24, 2020Phase 2 study in Carcinoma, Non-Small-Cell LungNCT04495153 · 90 enrolled · United States
- Dec 17, 2025Phase 2 study in Prostatic NeoplasmsNCT07332000 · 45 planned · United States
- Jun 5, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungNCT07660094 · 500 planned · United States
Ahead
- Feb 2027Primary completion: phase 2 study in Prostatic NeoplasmsNCT07332000
- Oct 22, 2031Primary completion: phase 3 study in Carcinoma, Non-Small-Cell LungNCT07660094
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07660094Carcinoma, Non-Small-Cell Lung · United States | 3 | Recruiting | Oct 22, 2031 | 500 |
| NCT07332000Prostatic Neoplasms · United States | 2 | Recruiting | Feb 2027 | 45 |
| NCT04495153Carcinoma, Non-Small-Cell Lung · United States | 2 | Active, not recruiting | Dec 31, 2024 | 90 |
| NCT03131037Lung Neoplasms · United States | 1 | Completed | Dec 1, 2021 | 12 |
| NCT02768363Prostatic Neoplasms · United States, Mexico | 2 | Active, not recruiting | Nov 2024 | 187 |
| NCT02446093Borderline Resectable Pancreatic Adenocarcinoma · United States, Mexico | 2 | Active, not recruiting | Dec 2025 | 54 |
| NCT01997190Pleural Effusion, Malignant · United States | 1 | Completed | Dec 2015 | 19 |
| NCT01436968Prostatic Neoplasms · United States, Puerto Rico | 3 | Active, not recruiting | Aug 2024 | 711 |
| NCT00751270Glioma · United States | 1 | Completed | Jan 2010 | 15 |
| NCT00638612Pancreatic Neoplasms · United States | 1 | Completed | May 2013 | 27 |
| NCT00634231Glioma · United States | 1 | Completed | Dec 2015 | 8 |
| NCT00589875Glioma · United States | 2 | Completed | Dec 2015 | 52 |
How it is read
Names in the registry
- “AdV-tk”, 3 entries
- “Aglatimagene besadenovec”, 2 entries
- “Aglatimagene besadenovec + valacyclovir”, 1 entry
- “aglatimagene besadenovec”, 1 entry
- “aglatimagene besadenovec + valacyclovir”, 1 entry
Conditions, from the studies’ own filings
- Prostatic Neoplasms, 3 studies
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Glioblastoma, 2 studies
- Lung Neoplasms, 1 study
- Ependymoma, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.